Study to Evaluate DNL201 in Subjects With Parkinson's Disease

Completed · Phase 1 · Has a placebo group

Conditions studied: Parkinson Disease

In brief

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple oral doses of DNL201 in subjects with Parkinson's disease.

Key facts

Study ID

NCT03710707

Run by

Denali Therapeutics Inc.

People needed

29

Starts

2018-12-04

Expected to finish

2019-12-06

Last updated by the study team

2020-01-13

Who can join

Age: 30 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Clinical Site(s) — Long Beach, California, United States
• Clinical Site(s) — Aurora, Colorado, United States
• Clinical Site(s) — Miami, Florida, United States
• Clinical Site(s) — Orlando, Florida, United States
• Clinical Site(s) — Farmington Hills, Michigan, United States
• Clinical Site(s) — Philadelphia, Pennsylvania, United States
• Clinical Site(s) — Spokane, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.